FDA Encourages Pediatric Master Protocols With Bayesian Approach
Executive Summary
Most trials currently use of frequentist statistics, but agency argues that Bayesian methods allow for better extrapolation.
You may also be interested in...
Mutual Recognition's Next Evolution May Be Sharing Info On India And China Inspections
Now that US FDA has approved the final EU authority, mutual recognition efforts could expand and deepen. Former FDA chief counsel Rebecca Wood discusses the future of approval standards harmonization in Pink Sheet interview.
US FDA's Brexit: One Staffer Moving, But Impact Still May Loom Large
Uncertainty about Brexit's impact on the FDA-EMA mutual recognition agreement are among issues worrying regulators as countdown continues to the UK's departure from the EU.
Orphan Drug Development: Could We Be Seeing The End Of P Values?
Panel of experts stresses need to move toward innovative approaches for rare disease drug development such as Bayesian methods, but this would require a paradigm shift in US FDA's regulatory structure.